^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Rectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor) +
    Lumakras (sotorasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/21/2023
    Excerpt:
    Rectal Cancer: SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE…Sotorasib + panitumumab (KRAS G12C mutation positive)…
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Excerpt:
    Vectibix (Panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with sotorasib, for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy